

5P.1834

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Christine L. Brakel et al.

Serial No.

08/479,999

Filed:

June 28, 1994

Title:

MODIFIED NUCLEOTIDE

COMPOUNDS

110311

Group Art Unit: 1809

Ex'r: Ardin H. Marschel

527 Madison Avenue, 9th Floor New York, New York 10022 February 6, 1998

FILED BY FIRST CLASS MAIL

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Box AF

RECEIVED

FEB 20 1993

MATRIX CUSTOMER SERVICE CENTER

COMMMUNICATION IN CONNECTION WITH APPLICANTS' FEBRUARY 5, 1998 FILINGS

Dear Sirs:

This Communication follows and is directed to Applicants' filings on February 5, 1998 in connection with the above-identified application. Those filings consisted of:

- Request For an Extension Of Time (Three Months) Under 37 C.F.R. §1.136(a);
- 2) a Response Under 37 C.F.R. §1.116 And Request Under 37 C.F.R. § 1.129(a) For Withdrawal Of the Finality Of The August 5, 1997 Office Action; and
- 3) a Request Under 37 C.F.R. § 1.129(a) For Withdrawal Of the Finality Of The August 5, 1997 Office Action.

From previous experience the undersigned attorney understands that the Rule 1.129(a) Request is usually granted for applications such as the present application filed before June 1995. Accordingly, any Notice of Appeal is not processed as a result of the finality of any outstanding Office Action having been withdrawn. In light of

03/12/1998 PDELOATC 00000003 DAM:051135 08479999 01 FC:217 475.00 CH

475.00 CH 395.00 CH

ENZ-47(C2)

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner of Palents & Trademarks Washington, DC 20231

Ronald C. Fedus Reg. No. 32.567 78 6 98 Date